Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 8,480 | 957 | 7,442 |
| Samples | 1,451 | 262 | 1,169 |
| Peptides | 1,244 | 202 | 1,060 |
Function
PTPRB · Protein tyrosine phosphatase receptor type B
The protein encoded by this gene is a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. This PTP contains an extracellular domain, a single transmembrane segment and one intracytoplasmic catalytic domain, thus belongs to receptor type PTP. The extracellular region of this PTP is composed of multiple fibronectin type_III repeats, which was shown to interact with neuronal receptor and cell adhesion molecules, such as contactin and tenascin C. This protein was also found to interact with sodium channels, and thus may regulate sodium channels by altering tyrosine phosphorylation status. The functions of the interaction partners of this protein implicate the roles of this PTP in cell adhesion, neurite growth, and neuronal differentiation. Alternate transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2011].
Isoforms & Proteins
6 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 1170 amino-acid changes on canonical ENST00000334414 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in PTPRB · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in PTPRB – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 11/40 28% | 0/0 0% |
| Melanoma | 36/210 17% | 260/1899 14% |
| Endometrial Carcinoma | 13/42 31% | 51/612 8% |
| Acute Myeloid Leukemia | 6/90 7% | 0/0 0% |
| Non-Small Cell Lung Carcinoma | 34/304 11% | 78/1390 6% |
| Squamous Cell Lung Carcinoma | 5/57 9% | 45/810 6% |
| Chondrosarcoma | 3/14 21% | 2/75 3% |
| Oral Cavity Carcinoma | 3/54 6% | 0/0 0% |
| Small Cell Lung Carcinoma | 2/9 22% | 36/752 5% |
| Other Solid Cancers | 9/94 10% | 60/1515 4% |
| Neuroendocrine Tumour | 22/154 14% | 8/577 1% |
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 5/133 4% |
| Hepatocellular Carcinoma | 3/46 7% | 75/2210 3% |
| Colorectal Carcinoma | 26/143 18% | 88/3239 3% |
| Ovarian Carcinoma | 11/109 10% | 26/998 3% |
| Germ Cell Tumour | 1/25 4% | 5/169 3% |
| Esophageal Squamous Cell Carcinoma | 7/51 14% | 72/2550 3% |
| Bladder Carcinoma | 0/58 0% | 28/956 3% |
| Other Sarcomas | 3/69 4% | 18/699 3% |
| Gastric Carcinoma | 2/74 3% | 49/1809 3% |
| Unknown | 1/10 10% | 0/29 0% |
| Rhabdomyosarcoma | 0/33 0% | 5/171 3% |
| Cervical Carcinoma | 4/35 11% | 7/422 2% |
| Head and Neck Carcinoma | 2/85 2% | 38/1574 2% |
| Esophageal Carcinoma | 0/23 0% | 18/769 2% |
| Hodgkins Lymphoma | 2/16 12% | 1/122 1% |
| Biliary Tract Carcinoma | 1/54 2% | 17/950 2% |
| Burkitts Lymphoma | 4/32 12% | 0/196 0% |
| Breast Carcinoma | 10/144 7% | 49/3264 2% |
Mutation Distribution
Where PTPRB is mutated · all tissues, split by cell line vs tissue
How many mutations in PTPRB were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 8,480 mutations in PTPRB
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|